Abnormal Platelet Serotonin Uptake and Binding Sites in Myeloproliferative Disorders

Summary

A simultaneous investigation of the kinetics of serotonin (5 HT) uptake and of binding sites was carried out in the platelets of normal subjects and of 10 patients affected with various types of myeloproliferative disorders (MD). The 5 HT uptake was analysed according to the Lineweaver-Burk and the Eadie-Hofstee methods. With the two methods, the patient’s platelets exhibited a dramatic reduction of the Vi max and of the Km; in some patients the Eadie-Hofstee analysis revealed that a passive diffusion phenomenon is superimposed on the active 5 HT uptake at least for the higher concentration used. The binding data were analysed with the Scatchard method. Two classes of binding sites (high affinity - low capacity, low affinity - high capacity) were found in normal subjects and patients. Pharmacological studies with imipramine, a specific inhibitor of 5 HT uptake, suggested that both the sites are involved in 5 HT uptake. The number of both binding sites was significantly decreased in patient’s platelets while the affinity constants of these binding sites were not significantly reduced in comparison with those of the control subjects. No correlations were found between Vi max, Km and the number of binding sites. These results suggest that a reduction in the number of platelet membrane acceptors for 5 HT commonly occurs in myeloproliferative disorders but does not provide a full explanation of the uptake defect.

Keywords

Myeloproliferative disorders - Platelet serotonin uptake - Platelet serotonin binding sites

• References

• 1 Rendu F, Lebret M, Nurden AT, Caen JR. Detection of an acquired platelet storage pool disease in three patients with a myeloproliferative disorder. Thromb Haemostas 1979; 42: 794-796
• 2 Caranobe C, Sié P, Nouvel C, Laurent G, Pris J, Boneu B. Platelets in myeloproliferative disorders II: Serotonin uptake and storage: correlations with mepacrine labelled dense bodies and with platelet density. Scand J Haematol 1980; 25: 289-95
• 3 Hardisty RM, Wolff HH. Haemorrhagic thrombocythaemia: a clinical and laboratory study. Br J Haematol 1955; 1: 390-405
• 4 McClure PD, Ingram GI C, Stacey RS, Glass UH, Matchett MO. Platelet function tests in thrombocythaemia and thrombocytosis. Br J Haematol 1966; 12: 478-497
• 5 Spaet TH, Lejnieks I, Gaynor E, Goldstein ML. Defective platelets in essential thrombocythaemia. Arch Intern Med 1969; 124: 135-141
• 6 Ts’ao CH, Rossi EC, Lestina FC. Abnormalities in platelet function and morphology in a case of thrombocythaemia. Arch Pathol Lab Med 1977; 101: 526-533
• 7 Gerrard JM, Stoddard SF, Shapiro RS, Coccia PF, Ramsay NK C, Nesbit ME, Rao GH R, Krivit W, White JG. Platelet storage pool deficiency and prostaglandin synthesis in chronic granulocytic leukaemia. Br J Haematol 1978; 40: 597-607
• 8 Caen JP, Sultan Y, Delobel J. Les thrombopathies acquises. Nouv Rev Fr Hematol 1969; 9: 553-569
• 9 Maldonado JE, Pintado T, Pierre RV. Dysplastic platelets and circulating megakaryocytes in chronic myeloproliferative diseases. I. The platelets: Ultrastructure and Peroxidase Reaction. Blood 1974; 43: 797-809
• 10 Sneddon JM. In: Progress in Neurobiology. Kerkut GA, Phillis JW. (eds) pp 151-198 Pergamon Press; Oxford: 1973
• 11 Malgrem R, Olsson P, Tornling G, Unge G. The 5-hydroxytryptamine take-up mechanism in normal platelets and platelets from migraine and asthmatic patients. Thromb Res 1980; 18: 733-741
• 12 Malgrem R. Methodological aspects of studies on the 5 HT uptake mechanism in normal platelets. Acta Pharmacol Toxicol 1981; 49: 277-284
• 13 Boullin DJ, Glenton PA M, Molyneux D, Peters JR, Roach B. Binding of 5-hydroxytryptamine to human blood platelets. Br J Pharmacol 1977; 61: 453
• 14 Boullin DJ, Molyneux D, Roach B. The binding of haloperidol to human blood platelets and interactions with 5-hydroxytryptamine and dopamine. Br J Pharmacol 1978; 63: 561-566
• 15 Kim BK, Steiner M, Baldim MG. Serotonin binding sites of human blood platelets. Anal Biochem 1980; 106: 92-98
• 16 Peters JR, Elliot JM, Grahame-Smith DG. Effect of oral contraceptive on platelet noradrenaline and 5-hydroxytryptamine receptors and aggregation. Lancet 1979; 3: 933-936
• 17 Schick PK, McKean ML. Serotonin binding in human platelets. Biochem Pharmacol 1979; 28: 2667-2670
• 18 Drummond AM, Gordon JL. Inhibition of H³ 5-hydroxytryptamine binding to rat blood platelets by 5 HT antagonists and uptake inhibitors. Brit J Pharmacol 1975; 55: 257-258
• 19 Drummond AM, Gordon JL. Specific binding sites for 5-hydroxytryptamine on rat blood platelets. Biochem J 1975; 150: 129-132
• 20 Costa JL, Murphy DL. Platelet 5 HT uptake and release stopped rapidly by formaldehyde. Nature 1975; 255: 407-408
• 21 Scatchard G. The attractions of proteins for small molecules and ions. Ann NY Acad Sci 1949; 51: 660-672
• 22 Costa JL, Silber SA, Murphy DL. Effects of reserpine and imipramine on vesicular serotonin uptake and storage in intact human platelets. Life Sciences 1977; 21: 181-188
• 23 Reimers HJ, Allen DJ, Cazenave JP, Feuerstein IA, Mustard JF. Serotonin transport and storage in rabbit blood platelets. The effects of reserpine and imipramine Biochem Pharmacol 1977; 26: 1645-1655
• 24 Wielosz M, Salmona M, De GaetanoG, Garattini S. Uptake of ¹⁴C 5-hydroxytryptamine by human and rat platelets and its pharmacological inhibition. Arch Pharmacol 1976; 296: 59-65
• 25 Ambrus JL, Ambrus CM, Thurber L. Study of platelet aggregation in vivo: V effect of the antiserotonin agent cyproheptadine. J Med 1977; 8: 317-320
• 26 Boullin DJ, Orr MW, Peters JR. In: Platelets: A multidisciplinary approach. De Gaetano G, Garatini S. (eds) pp 389-410 Raven Press; New York: 1978
• 27 Costa JL. Internalization of serotonin as a consequence of its association with human platelets at 0°. Biochem Pharmacol 1981; 30: 2662-2663